DFIB Cardiac Science (MM)

Distribution of Cardiac Science Powerheart(R) AEDs Begins to U.S. Hospitals IRVINE, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Cardiac Science Inc. (NASDAQ:DFIB) announced today that GE Healthcare, a division of General Electric Company (NYSE:GE), has initiated marketing and distribution of Cardiac Science's line of Powerheart(R)-branded automated external defibrillators (AEDs) and fully-automatic in-hospital defibrillator-monitors (CRMs) to hospitals in the United States and Canada. GE's sub-acute hospital sales force has begun marketing Cardiac Science's new Powerheart AED G3 PRO, Powerheart AED G3 and Powerheart CRM(TM) this week. Cardiac Science will support the GE sales effort via its regional sales specialists located in strategic North American locations. In November, Cardiac Science announced that it had expanded its multi-year strategic distribution agreement with GE Healthcare. GE is currently marketing a private-labeled version of the Powerheart AED G3 PRO device under the GE-brand name Responder(R) AED PRO outside the U.S. and Canada. Brad Jergenson GE's General Manager, Clinical Systems Sales said, "AEDs are clearly in demand within hospitals and are being used to treat patients in the non-acute sections of the hospital. The Powerheart AED G3 PRO with its unique features is designed specifically with physicians and nurses in mind. We also believe that the Powerheart CRM, given its small size and unique capabilities for automatic bedside monitoring and defibrillation, will provide our customers with a strong alternative to traditional crash cart defibrillators." About the Powerheart(R) AED G3 PRO The G3 PRO is a technologically advanced AED designed for use by sophisticated users of lifesaving equipment such as hospital personnel, medical professionals and emergency medical technicians. The G3 PRO is unique in that it displays the victim's heart rhythm on a built-in high resolution color electrocardiogram (ECG) display and gives professional users the option of delivering defibrillation shocks either semi-automatically or manually during the emergency treatment of victims of sudden cardiac arrest. Other advanced features include continuous cardiac monitoring capability via an ECG patient cable, multiple rescue data storage, clear and comprehensive AED and CPR voice prompts, infrared data transfer and optional rechargeable battery. About the Powerheart(R) Cardiac Rhythm Module (CRM) The CRM is a lightweight fully-featured external defibrillator that offers a complete therapeutic monitoring package in a single device -- continuous cardiac monitoring, synchronized cardioversion, non-invasive pacing as well as manual, semi-automatic or fully-automatic defibrillation. Designed for use in hospitals, the CRM can be used to monitor patients during transport, as an emergency defibrillator or be prophylactically attached to an at-risk cardiac patient. Once attached to the patient via its disposable electrode pads and programmed, the CRM can operate without the need for human intervention. It continuously monitors a patient's heart, detects the onset of life-threatening arrhythmias and can automatically deliver defibrillation therapy to patients suffering from Sudden Cardiac Arrest. About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automated public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company makes the Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call 1.949.797.3800. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the achievement of future revenue growth based on the expanded agreement with GE. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2003, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission. Contact: Matt Clawson (Investors) Michael D. Gioffredi Allen & Caron Inc Chief Marketing Officer (949) 474-4300 Cardiac Science, Inc. (949) 797-3800 DATASOURCE: Cardiac Science, Inc. CONTACT: Investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright